Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Precigen (PGEN – Research Report). The associated price target remains the same with $6.00.
Jason Butler’s rating is based on several strategic developments at Precigen that position the company favorably for future growth. The anticipation of FDA approval and subsequent launch of PRGN-2012, a promising therapeutic candidate, is a key factor. The company has made significant strides in commercial and manufacturing readiness, including upgrading its facilities and forming strategic partnerships to ensure a successful product launch.
Additionally, the positive outcomes from clinical trials, particularly the high response rates in patients treated with PRGN-2012, bolster confidence in the product’s market potential. Precigen’s ongoing trials for other candidates, such as PRGN-2009 and PRGN-3006, further demonstrate the robustness of its pipeline. These factors collectively support Jason Butler’s Buy rating, reflecting optimism about Precigen’s future performance.
According to TipRanks, Butler is an analyst with an average return of -5.5% and a 38.20% success rate. Butler covers the Healthcare sector, focusing on stocks such as Cytokinetics, Precigen, and Halozyme.